ATE168011T1 - Verwendung von einem cgrp antagonist für dir behandlung von hauterythemen neurogenischen ursprung und erhaltene zubearbeitung - Google Patents

Verwendung von einem cgrp antagonist für dir behandlung von hauterythemen neurogenischen ursprung und erhaltene zubearbeitung

Info

Publication number
ATE168011T1
ATE168011T1 AT96400457T AT96400457T ATE168011T1 AT E168011 T1 ATE168011 T1 AT E168011T1 AT 96400457 T AT96400457 T AT 96400457T AT 96400457 T AT96400457 T AT 96400457T AT E168011 T1 ATE168011 T1 AT E168011T1
Authority
AT
Austria
Prior art keywords
hydrams
skin
treatment
cgrp antagonist
received processing
Prior art date
Application number
AT96400457T
Other languages
English (en)
Inventor
Lacharriere Olivier De
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE168011(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Application granted granted Critical
Publication of ATE168011T1 publication Critical patent/ATE168011T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96400457T 1995-03-28 1996-03-04 Verwendung von einem cgrp antagonist für dir behandlung von hauterythemen neurogenischen ursprung und erhaltene zubearbeitung ATE168011T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503628A FR2732221B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue

Publications (1)

Publication Number Publication Date
ATE168011T1 true ATE168011T1 (de) 1998-07-15

Family

ID=9477498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96400457T ATE168011T1 (de) 1995-03-28 1996-03-04 Verwendung von einem cgrp antagonist für dir behandlung von hauterythemen neurogenischen ursprung und erhaltene zubearbeitung

Country Status (15)

Country Link
US (2) US5932215A (de)
EP (1) EP0734729B2 (de)
JP (1) JPH08268874A (de)
AR (1) AR002974A1 (de)
AT (1) ATE168011T1 (de)
BR (1) BR9601478A (de)
CA (1) CA2172777C (de)
DE (1) DE69600399T3 (de)
DK (1) DK0734729T4 (de)
ES (1) ES2121461T5 (de)
FR (1) FR2732221B1 (de)
HU (1) HUP9600765A3 (de)
MX (1) MX9601150A (de)
PL (1) PL313515A1 (de)
RU (1) RU2152798C1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
FR2768621B1 (fr) * 1997-09-22 2000-04-07 Oreal Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
WO2002089743A2 (en) * 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
DE60326370D1 (de) 2002-08-12 2009-04-09 Actavis Group Hf Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
CN101065014A (zh) * 2004-09-23 2007-10-31 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
ES2664854T3 (es) 2005-11-14 2018-04-23 Teva Pharmaceuticals International Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina para tratar cefalea en racimos
CN101959528A (zh) 2008-03-04 2011-01-26 辉瑞有限公司 治疗慢性疼痛的方法
US8367122B2 (en) * 2008-06-11 2013-02-05 Biochemics, Inc. Control of blood vessel physiology to treat skin disorders
CA2749941C (en) 2008-09-10 2018-04-24 Biochemics, Inc. Ibuprofen for topical administration
US9566256B2 (en) * 2008-09-22 2017-02-14 Biochemics, Inc. Transdermal drug delivery using an osmolyte and vasoactive agent
US9278233B2 (en) * 2008-12-04 2016-03-08 Biochemics, Inc. Methods and compositions for tattoo removal
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
CA2771186C (en) 2009-08-28 2018-01-02 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
WO2011109469A1 (en) 2010-03-03 2011-09-09 Neocutis Sa Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
BR112012024289A2 (pt) 2010-03-26 2017-07-18 Galderma Res & Dev "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
RS61793B1 (sr) 2011-05-20 2021-06-30 H Lundbeck As Anti-cgrp kompozicije i njihova upotreba
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
DK2709663T3 (da) 2011-05-20 2019-05-20 Alderbio Holdings Llc Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
SI3119431T1 (sl) 2014-03-21 2024-06-28 Teva Pharmaceuticals International Gmbh Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
EP3313518A1 (de) * 2015-06-29 2018-05-02 Galderma Research & Development Cgrp-rezeptor-antagonistenverbindungen zur topischen behandlung von hauterkrankungen
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
TW263498B (de) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
EP0751789B1 (de) * 1994-03-21 2001-11-07 BROWN THOMSEN, John Gel zur behandlung von hauterkrankungen und zur desinfizierung von haut
DE69529043T2 (de) * 1994-09-30 2003-05-08 L'oreal S.A., Paris Verwendung von einem Agonisten eines mit einem Chloridkanal assozierten Rezeptors zur Behandlung von Hautfalten
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
FR2728169A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728265A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
CA2172777C (fr) 2007-07-24
ES2121461T5 (es) 2005-05-01
EP0734729B1 (de) 1998-07-08
FR2732221B1 (fr) 1997-04-25
ES2121461T3 (es) 1998-11-16
DE69600399T2 (de) 1998-10-29
CA2172777A1 (fr) 1996-09-29
HUP9600765A2 (en) 1997-06-30
JPH08268874A (ja) 1996-10-15
MX9601150A (es) 1997-02-28
PL313515A1 (en) 1996-09-30
DK0734729T4 (da) 2004-10-25
FR2732221A1 (fr) 1996-10-04
RU2152798C1 (ru) 2000-07-20
US6509014B1 (en) 2003-01-21
AR002974A1 (es) 1998-05-27
DE69600399T3 (de) 2005-07-14
HU9600765D0 (en) 1996-05-28
DE69600399D1 (de) 1998-08-13
DK0734729T3 (da) 1999-04-19
BR9601478A (pt) 1998-06-02
US5932215A (en) 1999-08-03
EP0734729B2 (de) 2004-09-29
EP0734729A1 (de) 1996-10-02
HUP9600765A3 (en) 1998-04-28

Similar Documents

Publication Publication Date Title
ATE168011T1 (de) Verwendung von einem cgrp antagonist für dir behandlung von hauterythemen neurogenischen ursprung und erhaltene zubearbeitung
DE69637073D1 (de) Prozessor und verarbeitungsverfahren für dokumente
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
DE69941266D1 (de) Batchweise behandlung von job-signalen in einem multiverarbeitungssystem
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
DE69832838D1 (de) Vorrichtung zur Aufbewahrung und/oder Behandlung von Chemikalien
DE69421100D1 (de) Aufbereitung von schweren endprodukten des fischer-tropsch-verfahrens
DE69435249D1 (de) Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel
DE69625517D1 (de) 3-spiro-indolin-2-onderivate als liganden der vasopressin und/oder der ocytocin rezeptoren
DE69832393D1 (de) Spracherkennungssystem für die erkennung von kontinuierlicher und isolierter sprache
DE69310677D1 (de) Behandlung von Brennstoffgasen, insbesondere für Brennstoffzellen und Vorrichtung dafür
DE69626324D1 (de) Prozess zur verminderung des säuregehaltes und der korrosivität von rohöl
DE69014030D1 (de) Mittel für die Verhütung und Behandlung von Diarrhöe.
DE69222258D1 (de) Einrichtung und Verfahren für die Behandlung von Aussenwänden
DE69625769D1 (de) Verteiler zur unabhängigen Ein- und/oder Abführung von Fluiden
FR2714829B1 (fr) Composition cosmétique et/ou dermatologique pour le traitement du vieillissement contenant des céramides, son utilisation.
DE59601624D1 (de) Verwendung von 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
ATE278400T1 (de) Zusammensetzungen für die verwendung bei der behandlung und prävention von hyperurikämie
DE69501493D1 (de) Entfernung von Feuchtigkeit und Passivierung von Oberflächen
ATE318602T1 (de) Kombination aus einem alpha-1-adrenorezeptor antagonisten und einem cgm pdev hemmer zur behandlung von impotenz
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
ATE201828T1 (de) Verwendung eines cgrp antagonisten zur behandlung von flechten und pruritus und so erhaltene zubereitung
ATE205089T1 (de) Verwendung von einem cgrp antagonist für die behandlung von augen oder augenlidpruritus und dysesthesien
ATE202552T1 (de) Benzamide für behandlung von neurodegenerativen störungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee